{"id":1300,"date":"2024-03-23T08:16:36","date_gmt":"2024-03-23T08:16:36","guid":{"rendered":"https:\/\/internationaljournalofmicrobialscience.com\/?page_id=1300"},"modified":"2024-03-23T08:16:36","modified_gmt":"2024-03-23T08:16:36","slug":"references-40","status":"publish","type":"page","link":"https:\/\/internationaljournalofmicrobialscience.com\/index.php\/references-40\/","title":{"rendered":"References"},"content":{"rendered":"

 <\/p>\n

    \n
  1. Canou\u00ef, E., & Launay, O. (2019). Histoire et principes de la vaccination [History and principles of vaccination].\u00a0Revue des maladies respiratoires<\/em>,\u00a0 36<\/em>(1), 74\u201381. https:\/\/doi.org\/10.1016\/j.rmr.2018.02.015<\/a><\/li>\n
  2. Cunningham, A. L., Gar\u00e7on, N., Leo, O., Friedland, L. R., Strugnell, R., Laup\u00e8ze, B., Doherty, M., & Stern, P. (2016). Vaccine development: From concept to early clinical testing.\u00a0Vaccine<\/em>,\u00a034<\/em>(52),6655\u20136664. https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.016<\/a><\/li>\n
  3. Blattner, C., Lee, J. H., Sliepen, K., Derking, R., Falkowska, E., de la Pe\u00f1a, A. T., Cupo, A., Julien, J. P., van Gils, M., Lee, P. S., Peng, W., Paulson, J. C., Poignard, P., Burton, D. R., Moore, J. P., Sanders, R. W., Wilson, I. A., & Ward, A. B. (2014). Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.\u00a0Immunity<\/em>,\u00a040<\/em>(5),669\u2013680. https:\/\/doi.org\/10.1016\/j.immuni.2014.04.008<\/a><\/li>\n
  4. Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., Ahuja, A., Yung, M. Y., Leung, C. B., To, K. F., Lui, S. F., Szeto, C. C., Chung, S., & Sung, J. J. (2003). A major outbreak of severe acute respiratory syndrome in Hong Kong.\u00a0The New England journal of medicine<\/em>,\u00a0 348 <\/em>(20), 1986\u20131994. https:\/\/doi.org\/10.1056\/NEJMoa030685<\/a><\/li>\n
  5. Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K., Lau, E., Wong, J. Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., Tu, W., \u2026 Feng, Z. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.\u00a0The New England journal of medicine<\/em>, \u00a0382<\/em>(13), 1199\u20131207. https:\/\/doi.org\/10.1056\/NEJMoa2001316<\/a><\/li>\n
  6. World Health Organization (2020). https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020<\/a><\/li>\n
  7. Schoeman, D., & Fielding, B. C. (2019). Coronavirus envelope protein: current knowledge.\u00a0Virology journal<\/em>,\u00a016<\/em>(1), 69. https:\/\/doi.org\/10.1186\/s12985-019-1182-0<\/a><\/li>\n
  8. Malczyk, A. H., Kupke, A., Pr\u00fcfer, S., Scheuplein, V. A., Hutzler, S., Kreuz, D., Beissert, T., Bauer, S., Hubich-Rau, S., Tondera, C., Eldin, H. S., Schmidt, J., Vergara-Alert, J., S\u00fczer, Y., Seifried, J., Hanschmann, K. M., Kalinke, U., Herold, S., Sahin, U., Cichutek, K., \u2026 M\u00fchlebach, M. D. (2015). A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.\u00a0Journal of virology<\/em>, \u00a089<\/em>(22), 11654\u201311667. https:\/\/doi.org\/10.1128\/JVI.01815-15<\/a><\/li>\n
  9. Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., Gao, H., Ge, X., Kan, B., Hu, Y., Liu, J., Cai, F., Jiang, D., Yin, Y., Qin, C., Li, J., \u2026 Qin, C. (2020). Development of an inactivated vaccine candidate for SARS-CoV-2.\u00a0Science (New York, N.Y.)<\/em>,\u00a0369<\/em>(6499), 77\u201381. https:\/\/doi.org\/10.1126\/science.abc1932<\/a><\/li>\n
  10. Al-Kassmy, J., Pedersen, J., & Kobinger, G. (2020). Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? Viruses<\/em>,\u00a012<\/em>(8), 861. https:\/\/doi.org\/10.3390\/v12080861<\/a><\/li>\n
  11. Callaway E. (2020). Coronavirus vaccine trials have delivered their first results – but their promise is still unclear.\u00a0Nature<\/em>,\u00a0581<\/em>(7809),363\u2013364. https:\/\/doi.org\/10.1038\/d41586-020-01092-3<\/a><\/li>\n
  12. Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) against Novel Coronavirus, Moderna, Inc. 2020. Available online: https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine<\/a><\/li>\n
  13. Amanat, F., & Krammer, F. (2020). SARS-CoV-2 Vaccines: Status Report.\u00a0 Immunity<\/em>,\u00a052<\/em>(4), 583\u2013589. https:\/\/doi.org\/10.1016\/j.immuni.2020.03.007<\/a><\/li>\n
  14. Noah C Peeri, Nistha Shrestha, Md Siddikur Rahman, Rafdzah Zaki, Zhengqi Tan, Saana Bibi, Mahdi Baghbanzadeh, Nasrin Aghamohammadi, Wenyi Zhang and Ubydul Haque. https:\/\/www.forbes.com\/sites\/moneyshow\/2020\/06\/16\/9-pharmaceutical-companies-racing-for-a-covid-19-vaccine\/#7680f63476ad<\/a><\/li>\n
  15. Yan-JunZhang,\u00a0Gang\u00a0Zeng,\u00a0Hong-Xing\u00a0Pan,\u00a0Chang-Gui\u00a0Li,\u00a0Biao\u00a0Kan,\u00a0Ya-Ling\u00a0Hu,\u00a0Hai-Yan\u00a0Mao,\u00a0Qian Qian\u00a0Xin,\u00a0Kai\u00a0Chu,\u00a0Wei-Xiao\u00a0Han,\u00a0Zhen\u00a0Chen,\u00a0Rong\u00a0Tang,\u00a0Wei-Dong\u00a0Yin,\u00a0Xin\u00a0Chen,\u00a0Xue-Jie\u00a0Gong,\u00a0Chuan\u00a0Qin,\u00a0Yuan-Sheng\u00a0Hu,\u00a0Xiao-Yong\u00a0Liu,\u00a0Guo-Liang\u00a0Cui,\u00a0Cong-Bing\u00a0Jiang,\u00a0Heng-Ming\u00a0Zhang,\u00a0Jing-Xin\u00a0Li,\u00a0Min-Nan\u00a0Yang,\u00a0Xiao Juan\u00a0Lian,\u00a0Yan\u00a0Song,\u00a0Jin-Xing\u00a0Lu,\u00a0Xiang-Xi\u00a0Wang,\u00a0Miao\u00a0Xu,\u00a0Qiang\u00a0Gao,\u00a0Feng-Cai\u00a0Zhu(2020). Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial. MedRxiv. COVID-19 SARS-CoV2 preprints from medRxiv and bioRxiv<\/a>. This article is a preprint and has not been peer-reviewed. doi:<\/u>\u00a0<\/u>https:\/\/doi.org\/10.1101\/2020.07.31.20161216<\/a><\/li>\n
  16. Osterhaus, A. D., & Rimmelzwaan, G. F. (1998). Induction of virus-specific immunity by iscoms.\u00a0Developments in biological standardization<\/em>,\u00a092<\/em>, 49\u201358.<\/li>\n
  17. Magnusson, S. E., Reimer, J. M., Karlsson, K. H., Lilja, L., Bengtsson, K. L., & Stertman, L. (2013). Immune enhancing properties of the novel Matrix-M\u2122 adjuvant leads to potentiated immune responses to an influenza vaccine in mice.\u00a0Vaccine<\/em>,\u00a031<\/em>(13), 1725\u20131733. https:\/\/doi.org\/10.1016\/j.vaccine.2013.01.039<\/li>\n
  18. Reimer, J. M., Karlsson, K. H., L\u00f6vgren-Bengtsson, K., Magnusson, S. E., Fuentes, A., & Stertman, L. (2012). Matrix-M\u2122 adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen.\u00a0PloS one<\/em>,\u00a07<\/em>(7),e41451. https:\/\/doi.org\/10.1371\/journal.pone.0041451<\/a><\/li>\n
  19. Pedersen, G., Major, D., Roseby, S., Wood, J., Madhun, A. S., & Cox, R. J. (2011). Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.\u00a0Influenza and other respiratory viruses<\/em>,\u00a05<\/em>(6), 426\u2013437. https:\/\/doi.org\/10.1111\/j.1750-2659.2011.00256.x<\/a><\/li>\n
  20. Madhun, A. S., Haaheim, L. R., Nilsen, M. V., & Cox, R. J. (2009). Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.\u00a0Vaccine<\/em>,\u00a027<\/em>(52), 7367\u20137376. https:\/\/doi.org\/10.1016\/j.vaccine.2009.09.044<\/a><\/li>\n
  21. Radosevi\u0107, K., Rodriguez, A., Mintardjo, R., Tax, D., Bengtsson, K. L., Thompson, C., Zambon, M., Weverling, G. J., Uytdehaag, F., & Goudsmit, J. (2008). Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.\u00a0Vaccine<\/em>,\u00a026<\/em>(29-30),3640\u20133646. https:\/\/doi.org\/10.1016\/j.vaccine.2008.04.071<\/a><\/li>\n
  22. Rajput, Z. I., Hu, S. H., Xiao, C. W., & Arijo, A. G. (2007). Adjuvant effects of saponins on animal immune responses.\u00a0Journal of Zhejiang University. Science. B<\/em>,\u00a08<\/em>(3), 153\u2013161. https:\/\/doi.org\/10.1631\/jzus.2007.B0153<\/a><\/li>\n
  23. Cox, R. J., Pedersen, G., Madhun, A. S., Svindland, S., S\u00e6vik, M., Breakwell, L., Hoschler, K., Willemsen, M., Campitelli, L., N\u00f8stbakken, J. K., Weverling, G. J., Klap, J., McCullough, K. C., Zambon, M., Kompier, R., & Sjursen, H. (2011). Evaluation of a virosomal H5N1 vaccine formulated with Matrix M\u2122 adjuvant in a phase I clinical trial.\u00a0Vaccine<\/em>,\u00a029<\/em>(45),8049\u20138059. https:\/\/doi.org\/10.1016\/j.vaccine.2011.08.042<\/a><\/li>\n
  24. Study of parenterally administrated adjuvanted seasonal influenza vaccine in healthy elderly volunteers. Identifier: NCT01444482.<\/li>\n
  25. A (H7N9) VLP antigen dose-ranging study with Matrix-M1 adjuvant. Identifer: NCT02078674. [database on the Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02078674<\/a><\/li>\n
  26. Magnusson SE, Reimer JM, Karlsson KH, Lilja L, Bengtsson KL, Stertman L (2013). Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine,<\/em> 31<\/em>(13):1725\u201333. https:\/\/doi.org\/ 10.1016\/j.vaccine.2013.01.039<\/u><\/li>\n
  27. Cox, F., Roos, A., Hafkemeijer, N., Baart, M., Tolboom, J., Dekking, L., Stittelaar, K., Goudsmit, J., Rado\u0161evi\u0107, K., & Saeland, E. (2015). Matrix-M Adjuvated Seasonal Virosomal Influenza Vaccine Induces Partial Protection in Mice and Ferrets against Avian H5 and H7 Challenge.\u00a0PloS one<\/em>,\u00a010<\/em>(9), e0135723. https:\/\/doi.org\/10.1371\/journal.pone.0135723<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      Canou\u00ef, E., & Launay, O. (2019). Histoire et principes de la vaccination [History and principles of vaccination].\u00a0Revue des maladies respiratoires,\u00a0 36(1), 74\u201381. https:\/\/doi.org\/10.1016\/j.rmr.2018.02.015 Cunningham, A. L., Gar\u00e7on, N., Leo, O., Friedland, L. R., Strugnell, R., Laup\u00e8ze, B., Doherty, M., & Stern, P. (2016). Vaccine development: From concept to early clinical testing.\u00a0Vaccine,\u00a034(52),6655\u20136664. https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.016 Blattner, C., […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1300","page","type-page","status-publish","hentry"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t